Triazolo[4,5-d]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce...

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Cellular stress activates the integrated stress response (ISR) pathway, crucial for cell adaptation.
• The ISR pathway converges on eIF2α phosphorylation, regulated by kinases including GCN2.
• Selective chemical inhibitors for ISR kinases are available, but GCN2 inhibitors were lacking.

Purpose of the Study:

• To synthesize and evaluate novel, potent, and selective GCN2 kinase inhibitors.
• To validate these inhibitors as chemical probes for cellular studies.
• To explore the therapeutic potential of GCN2 inhibition in cancer, particularly leukemia.

Main Methods:

• Synthesis of GCN2 inhibitors using a triazolo[4,5-d]pyrimidine scaffold.
• In vitro enzyme inhibition assays and selectivity profiling against related kinases (PERK, HRI, IRE1).
• Cellular assays measuring eIF2α phosphorylation in HEK293T cells and screening against the NCI-60 cancer cell line panel.

Main Results:

• Several synthesized compounds potently inhibited GCN2 in vitro with good selectivity.
• The inhibitors effectively reduced eIF2α phosphorylation in cells (IC50 < 150 nM).
• Screening revealed uniform growth inhibition in leukemia cell lines, correlating with high GCN2 mRNA levels and low ASNS expression in B-ALL patients.

Conclusions:

• Novel GCN2 inhibitors were developed and validated as effective chemical probes.
• GCN2 inhibition demonstrates anti-leukemic activity, especially in B-cell acute lymphoblastic leukemia (B-ALL).
• High GCN2 and low ASNS expression in B-ALL suggests potential susceptibility to GCN2-targeted therapies.